It has been established that selective COX-2 inhibitors reduce breast cancer risk by promoting apoptosis, and by inhibiting cell proliferation and angiogenesis through decreased prostaglandin synthesis59, 60. This evidence concerns the gene PTGS2 and breast cancer.